Biotech | December 11, 2021
Alembic acquires stake in RIGlmmune
The company is focused on the development of novel treatments for RNA viruses
The company is focused on the development of novel treatments for RNA viruses
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Approximately five kg tumor was removed in the eight-hour long complicated surgery
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The company has has 10 existing labs in India
The funds will be used to scale up existing operations and launch new products
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Subscribe To Our Newsletter & Stay Updated
